两项新研究：铂耐药卵巢癌患者总生存期显著改善

Declaration of interests

NC reports grants or contracts from AstraZeneca and GSK (paid to institution), payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, MSD, GSK, Eisai, AbbVie, Pharma&, and Corcept; support for attending meetings or travel from GSK, AstraZeneca, and AbbVie; participation on a Data Safety Monitoring Board or Advisory Board from Roche, AstraZeneca, MSD, GSK, Immunogen, Eisai, Oncxerna, Nuvation Bio, Gilead, Regeneron, Novocure, Seagen, AbbVie, Lilly, BeOne, and Biontech; medical writing assistance from MSD; and participation in the Scientific Committee ACTO and the Member Nomination Committee ESMO (unpaid). EZ reports grants or contracts from MSD, NCI, DoD, and OCRA; consulting fees from MSD, AbbVie, NextCure, Iovance, 92Biotech, Takeda Oncology, and Apellis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events for AstraZeneca; and participation on a Data Safety Monitoring Board or Advisory Board for MSD. ER reports grants or contracts from AstraZeneca, Gilead, MSD, and Roche (paid to institution); and support for attending meetings or travel and participation in a Data Monitoring Committee from Philogen. AS reports Advisory Board and Data Safety Monitoring Board participation, and speaker's honorarium, from GSK, Eisai, and MSD. CG reports consulting fees from GSK, Gilead, MSD, and Adium; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, MSD, and Adium; and participation on a Data Safety Monitoring Board or Advisory Board from GSK, Gilead, and Adium. KH reports research contracts from Daiichi Sankyo, Eisai, MSD, and Takeda; consulting fees from Chugai, Fuji, and Kyowa Kirin; advisory board fees from Eisai, Takeda, MSD, Regeneron, Roche, Genmab, Sanofi, GSK, and Zymeworks; honoraria from Daiichi Sankyo, AstraZeneca, Chugai, Eisai, Fuji, Genmab, MSD, Takeda, Sanofi, Kyowa Kirin, Kaken, GSK, and Regeneron. MM-M reports research funding from MSD; grants or contracts from Eli Lilly, MSD, and Fortrea (paid to institution); Advisory Board and speaker fees from Eli-Lilly, Roche, Merck GA, MSD, and GSK; and support for attending meetings or travel from Novartis, Merck GA, and Servier. JRK reports grants or contracts from AstraZeneca, Novartis, Philips, Dutch Cancer Society, and Bontius Stichting/LUF (paid to institution); consulting fees from AstraZeneca, Eisai, GSK, Lilly, MSD, Novartis, and Daiichi Sankyo (paid to institution); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Eisai, GSK, and MSD (paid to institution); support for attending meetings or travel from Daiichi Sankyo (paid to institution); and participation on a Data Safety Monitoring Board or Advisory Board for DSMB, TEIPP, and Alison. ACdM reports grants or contracts, paid to institution, from Amgen, AstraZeneca, Bristol Myers, Squibb, Clovis Oncology, GSK, MSD, Novartis, Regeneron, and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Bristol Myers Squibb, GSK, MSD, Novartis, Adium, Daiichi, Pfizer, and AbbVie; support for attending meetings or travel from MSD, Daiichi, and AbbVie; and participation on a Data Safety Monitoring Board or Advisory Board from AstraZeneca, Bristol Myers Squibb, GSK, MSD, Novartis, Roche, and Daiichi. PRD reports consulting fees from MSD, Astellas, and Ipsen; support for attending meetings or travel from Ipsen and MSD; and stock or stock options from Mural Oncology and UCB. J-WK reports a leadership or fiduciary role in the Executive Board of the Asia-Pacific Gynecologic Cancer Trials Group. JS reports research funding from AstraZeneca, Bayer, Clovis Oncology, GSK, Iqvia, Lilly, MSD, Mural, Roche Pharma, and Tesaro (paid to institution); consulting fees from AstraZeneca, Bayer Vital, Bristol Myers, Clovis Oncology, Daiichi Sankyo, Eisai, Encare, Immunogen, Intuitive Surgical, Karyopharm Therapeutics, Merck/Pfizer, MSD, Mundipharma, Novocure, Oncoinvent, PharmaMar, Roche Pharma, Sanofi-Aventis Deutschland, Seagen, and Tubulis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AMGEN, AstraZeneca, Bayer, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo, Eisai, Esteve Pharmaceuticals, GSK, Hexal, Incyte Biosciences, Jenapharm, Kyowa Kirin, Medtronic Covidien, Novartis Pharma, Oncoinvent, Pharma&, PharmaMar, Phytolife Nutrition, Roche Pharma, and Vifor Pharma; support for attending meetings or travel from AstraZeneca, GSK, Roche Pharma, Novocure, Immunogen, Incyte, MSD, and Eisai; participation on a Data Safety Monitoring Board or Advisory Board for Immunogen, Incyte, GSK, AstraZeneca, Clovis, Novocure, Bristol Myers Squibb, MSD, Bayer, and PharmaMar; leadership or fiduciary role in European Society of Gynecological Oncology, North-Eastern German Society of Gynecological Oncology, Pan-Arabian Research Society for Gynecological Oncology, Deutsch-Türkische Gynäkologengesellschaft, Deutsche Stiftung Eierstockkrebs, Arbeitsgemeinschaft Gynäkologische Onkologie, and Charité Comprehensive Cancer Center; medical writing assistance from MSD; unpaid participation in editorial boards for International Journal of Gynecological Cancer, Journal of the Turkish-German Gynecological Association, Anticancer Research, Archives of Gyencology and Obstetrics, Research and Treatment, Annals of Gynecology and Obstetrics Research, Journal of Hematology & Multiple Myeloma, and guest editorship for Cancers. M-EP reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, AstraZeneca, AbbVie, Tecnofarma, Dr Reddy's, and MSD; and support for attending meetings or travel from GSK, AstraZeneca, Roche, AbbVie, and MSD. SH reports participation on a Data Safety Monitoring Board or Advisory Board and advisory or consulting fees from AstraZeneca, Eisai, MSD, GSK, and AbbVie. CZ reports honoraria for participation in the Delphi study from Daiichi Sankyo and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, MSD, Eisai, GSK, Menarini Stemline, Exact Sciences, and Gilead; support for attending meetings or travel from Roche, Novartis, Pfizer, AstraZeneca, Daiichi Sankyo, MSD, Eisai, GSK, and Gilead; and participation on a Data Safety Monitoring Board or Advisory Board for Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, MSD, Eisai, GSK, Menarini Stemline, Exact Sciences, and Gilead. BJM reports consulting fees from AstraZeneca, BioNtech, Corcept, DSI, Eisai, Eli Lilly, Genmab/Seagen/Pfizer, GOG Foundation, GSK, Immunogen/Abbvie, Incyte, Karyopharm, MSD, Mersana, Mural/Alkermes, Myriad, Natera, Novartis, Novocure, OncoC4, Panavance, Pharma&, ProfoundBio/Genmab, Regeneron, Roche/Genentech, Sutro, Tubulis, Verastem, Zentalis, and Zymeworks; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, DSI, Eisai, GSK, Immunogen/AbbVie, and MSD. RLC reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, MSD, GSK, Karyopharm, Faeth, Genmab, and DSI; participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Genmab/Seagen, GSK, Immunogen, Panavance, Profoundbio, and Roche/Genentech; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, as a steering committee member for AstraZeneca, GSK, MSD, Roche-Genentech, and Verastem; as a trial chair for Immonogen/AbbVie; as a coordinating principal investigator for Karyopharm; and as a principal investigator for AbbVie, Genmab, Immunogen, MSD, and Roche/Genentech. TDLMR reports grants or contracts from GSK (paid to institution); consulting fees from GSK, AstraZeneca, Eisai, MSD, Pfizer, Novartis, Gilead, AbbVie, Sanofi, and Regeneron; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, AstraZeneca, MSD, Pfizer, Gilead, and AbbVie; support for attending meetings or travel from Roche, Gilead, and MSD; and participation on a Data Safety Monitoring Board or Advisory Board for MSD. XP, KY, and AMB are employees of Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA, who may own stock or hold stock options in Merck & Co, Rahway, NJ, USA. All other authors declare no competing interests.

Declaration of interests

DL reports grants or contracts from AstraZeneca, AbbVie, GSK, Incyte, MSD, and Corcept; consulting fees from AstraZeneca, AbbVie, GSK, Genmab, MSD, and Pharma&; support for attending meetings or travel from GSK, AbbVie, AstraZeneca, and MSD; and participation on a data safety monitoring board or advisory board at AstraZeneca, AbbVie, Corcept, Genmab, GSK, Regeneron, and MSD. LGl reports support for attending meetings or travel from AbbVie and MSD. DMO reports support for the present manuscript from Corcept; grants or contracts from AbbVie, Advaxis, Agenus, Alkermes, Aravive, Arcus, AstraZeneca, BeiGene, Boston Biomedical, Bristol Myers Squibb, Clovis, Deciphera Pharma, Eisai, EMD Serono, Exelixis, Genentech, Genmab, GSK, the Gynecologic Oncology Group Foundation, F Hoffmann–La Roche, ImmunoGen, Incyte, IOVANCE, Karyopharm, Leap, the Ludwig Institute for Ca, Merck & Co, Merck Sharp & Dohme, Mersana, NCI, Novartis, NovoCure, NRG Oncology, OncoC4, OncoQuest, Pfizer, Precision Therapeutics, Prelude Therapeutics, Regeneron, the RTOG, Rubius Therapeutics, Seattle Genetics, Sutro Biopharma, SWOG, and Verastem; consulting fees from or advisory boards for AbbVie, AstraZeneca, Corcept, Duality Bio, Eli Lilly, GSK, the Gynecologic Oncology Group Foundation, Merck & Co, Merck Sharp & Dohme, Regeneron Pharmaceuticals, Verastem, and Zentalis; and a leadership or fiduciary role at the Gynecologic Oncology Group Foundation Board of Directors. AF reports grants or contracts from AstraZeneca and MSD; consulting fees from Oncoinvent; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Covidien/Medtronic, Pharmaand, and AbbVie; and participation on a data safety monitoring board or advisory board at GSK. LGi reports grants or contracts from Alkermes, Ascendis, AstraZeneca, Bayer, CanariaBio, Corcept Therapeutics, Daiichi Sankyo, Eisai, Espersas, Fortrea, Gilead Science, GOG Foundation, GSK, Immunogen, IMV, K-Group Beta, Karyopharm, Macrogenics, Merck, Mersana Therapeutics, Novocure, OncoQuest Pharmaceuticals, Paraxel International Therapeutics, Pfizer, Pri-Wex Pharma, Roche, Seagen, Shattuck Labs, Sichuan Kelun Biotech, Sutro Bio Pharma, Tesaro, and Verastem; consulting fees from Merck, AbbVie, and GSK; and participation on a data safety monitoring board or advisory board at Merck, GSK, Eisai, and Repare Therapeutics. LM reports medical writing support for this manuscript from Corcept. SQ reports payment or honoraria from AstraZeneca, GSK, MSD, Pharma&, Eisai, and AbbVie; support for attending meetings from GSK, MSD, Pharma&, Eisai, and AbbVie; and participation on a data safety monitoring board or advisory board at AstraZeneca, GSK, MSD, Pharma&, Eisai, and Servier. EH reports participation in advisory board meeting for Corcept. AO reports consulting fees from AbbVie, Agenus, AstraZeneca, Clovis, Corcept, Deciphera, Daiichi Sankyo, Debiopharm International, Eisai, Exelixis, F Hoffmann–La Roche, Genmab, GSK, ImmunoGen, Itheos, MSD, Mersana, Myriad Genetics, Novocure, OncoXerna, PharmaMar, Regeneron, Sattucklabs, Seagen/Pfizer, Stemline Therapeutics, Sutro Biopharma, TORL Bio Therapeutics, Zentalis, and Zymeworks; payment or honoraria from the NSGO, Peerview, Peervoice, Medscape, Asociación Colombiada de Ginecológos Oncólogos, the ESO, AstraZeneca, and GSK; support for attending meetings from AstraZeneca, PharmaMar, and Roche; and participation on a data safety monitoring board or advisory board for Agenus, AstraZeneca, Clovis Oncology, Corcept, Deciphera Pharmaceuticals, Daiichi Sankyo, Debiopharm International, Eisai, Exelixis, F Hoffmann–La Roche, Genmab, GSK, ImmunoGen, Itheos, MSD, Mersana, Myriad Genetics, Novocure, OncoXerna, PharmaMar, Regeneron, Sattucklabs, Seagen/Pfizer, Stemline Therapeutics, Sutro Biopharma, TORL Bio Therapeutics, Zentalis, and Zymeworks; and leadership or fiduciary roles at Gynecologic Cancer Intergroup cervical cancer committee chair; ESMO Gyn subject editor guidelines; ESMO Gyn meeting chair; and ESMO Gyn faculty member; and other financial or non-financial interests in Gynecologic Cancer Intergroup, European Society for Medical Oncology, American Society of Clinical Oncology, Spanish Society of Medical Oncology, and the GOG Foundation. MS reports research funding from AstraZeneca, AbbVie, and Gilead; consulting fees from GSK, AbbVie, MSD and AstraZeneca; payment or honoraria from MSD, GSK, AstraZeneca, and AbbVie; support for attending meetings from MSD, AstraZeneca, GSK, and Daiichi Sankyo; and participation on data safety monitoring or advisory boards for MSD, GSK, AstraZeneca, and AbbVie; and leadership or fiduciary role in Sociedade Brasileira de Oncologia Clínica. AC reports support for the present manuscript from Corcept; grants or contracts from Advenchen; payment or honoraria from AbbVie and Pharma&; and support for attending meetings or travel from AbbVie. CP reports stock or stock options in AbbVie, Johnson & Johnson, Pfizer, Amgen, Merck, Gilead, and Bristol Myers Squibb. VS reports payment or honoraria from MSD, AstraZeneca, GSK, Menarini, Pharma&, AbbVie, and Eisai; support for attending meetings or travel from MSD, AstraZeneca, Pharma&, and Menarini; and participation on a data safety monitoring board or advisory board at MSD, AstraZeneca, GSK, Pharma&, AbbVie, and Eisai. BJM reports consulting fees from AstraZeneca, BioNTech, Corcept, DSI, Eisai, Eli Lilly, Genmab–Seagen–Pfizer, the Gynecologic Oncology Group Foundation, GSK, ImmunoGen–AbbVie, Incyte, Karyopharm, Merck, Mersana, Mural/Alkermes, Myriad, Natera, Novartis, Novocore, OncoC4, Panavance, Pharmaand, ProfoundBio, Genmab, Regeneron, Roche–Genentech, Sutro Biopharma, Tubulis, Verastem Oncology, Zentalis, and Zymeworks; and payment or honoraria from AstraZeneca, DSI, Eisai, GSK, Immunogen/AbbVie, and Merck. PF reports consulting fees from AbbVie, GSK, Novartis, and Daiichi; payment or honoraria from MSD, AbbVie, and Novartis; payment for expert testimony from AbbVie, Regeneron, and GSK; support for attending meetings or travel from AbbVie, Novartis, and Daiichi; and participation on data safety monitoring or advisory boards for AbbVie. EM reports grants or contracts from Stanford Cancer Institute. BS reports consulting fees from MSD, AstraZeneca, Daiichi Sankyo, Incyte, Seagen, Novocure, Karyopharm, Genmab, Aadi, Regeneron, Immunocore, Gilead, Eisai, Beigene, and GSK. EG reports participation on data safety monitoring or advisory boards for Daiichi Sankyo, Amgen, and MSD; support for attending meetings or travel from MSD; and payment or honoraria from GSK, EISAI, MSD, and AstraZeneca. MCC reports support for attending meetings or travel from AstraZeneca. AD reports support for attending meetings or travel from GSK, Novartis, AstraZeneca, and Gilead. CC reports consulting fees, payment or honoraria, and participation on data safety monitoring or advisory boards for AstraZeneca and GSK; and leadership or fiduciary role at Abracadabra advocacy group. GA reports payment or honoraria from GSK, AstraZeneca, and Pharmaand; and support for attending meetings or travel from GSK and AstraZeneca. TVG reports grants or contracts from Amgen, AstraZeneca, and Roche; consulting fees from AbbVie, AstraZeneca, BeiGene, BioNTech, Cancer Communications and Consultancy, Daiichi Sankyo, Eisai, Eli Lilly, Genmab, GSK, ImmunoGen, Incyte, Karyopharm, MSD–Merck, OncXerna, Seagen, TORL Bio Therapeutics, Tubulis, Verastem, and Zentalis; honoraria for lectures from AbbVie, AstraZeneca, Eisai, GSK, ImmunoGen, and MSD; support for attending meetings from ImmunoGen, MSD, and PharmaMar; and leadership or fiduciary role as the Chair of the Belgian and Luxembourg Gynaecological Oncology Group. AS reports consulting fees from MSD, AstraZeneca, and AbbVie; payments or honoraria from MSD and AstraZeneca; support for attending meetings from AstraZeneca and MSD; and participation on a data safety monitoring board or advisory board at AstraZeneca, MSD, and AbbVie. LKD reports support for the present manuscript and stock or stock options in Corcept. AK-H reports stock or stock options in Corcept and Exelixis. ICT reports support for the present manuscript, employment, and stock or stock options in Corcept; and leadership or fiduciary role as Member of the Board of Directors at Bay Area Biotech-Pharma Statistics Workshop. AMJ reports employment and stock or stock options in Corcept. NC reports support for the present manuscript from Corcept; grants or contracts from AstraZeneca and GSK; payment or honoraria from AstraZeneca, GSK, MSD, AbbVie, Pharmaand, Corcept, and Eisai; support for attending meetings from GSK, AstraZeneca, and AbbVie; participation on data safety monitoring or advisory boards for Roche, AstraZeneca, MSD, Eisai, GSK, ImmunoGen, Oncxerna, Nuvation Bio, Gilead, Regeneron, Novocure, Seagen, AbbVie, Eli Lilly, BeOne, and Biontech; and a leadership role as Chair of the Alleanza Contro il Tumore Ovarico Scientific Committee, and a member of the nomination committee at ESMO. All other authors declare no competing interests.